MedTrace Logo

Warfarin and Antiplatelet Vascular Evaluation

NCT00125671 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2400

Last updated 2009-09-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether the addition of warfarin (a blood-thinning medication) to an antiplatelet therapy like aspirin is better than antiplatelet therapy alone (i.e. usual treatment) for the prevention of leg surgery, heart attacks, stroke and death in people with peripheral vascular disease.

Conditions

Interventions

DRUG

Warfarin

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Heart and Stroke Foundation of Ontario

    collaborator OTHER

  • Anand, Sonia, M.D.

    lead INDIV

Principal Investigators

  • Sonia Anand, MD PhD FRCPc · Population Health Research Institute, McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Completion
2006-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00125671 on ClinicalTrials.gov